Immunologically modified enzyme-responsive micelles regulate the tumor microenvironment for cancer immunotherapy

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• Immune checkpoint blockade revolutionized tumor treatment but faces limitations like low T cell response and immunosuppressive cells.
• Current single-target therapies are often compromised by complex tumor immune microenvironments.

Purpose of the Study:

• To develop a nano-delivery system for improved tumor immunotherapy.
• To combine an aryl hydrocarbon receptor (AhR) inhibitor with a T cell activator for synergistic antitumor effects.

Main Methods:

• Constructed a polypeptide-based micellar system encapsulating an AhR inhibitor (CH223191) conjugated to anti-CD28.
• Investigated the effect of AhR inhibition and T cell co-stimulation on the tumor immune microenvironment and tumor metastasis.

Main Results:

• Inhibition of AhR activation reduced immunosuppressive cells and tumor metastasis.
• Combination therapy enhanced T cell activation and synergistically improved antitumor efficacy.
• The developed micellar system demonstrated a novel and effective approach to tumor immunotherapy.

Conclusions:

• The novel micellar system effectively modulates the tumor immune microenvironment.
• This combined approach offers a promising strategy for enhancing cancer immunotherapy outcomes.